|
|
| Budesonide in a Nutshell |
| |
| |
Markets |
| |
- AstraZeneca currently markets budesonide under the brand name Pulmicort Respules
- According to the IMS National Sales Perspectives database, U.S. sales of Pulmicort Respules were over $700 million in 2006
|
| |
Product Advantages |
| |
- Faster onset of activity for both inhalation and nasal spray.
- Potential ability to deliver lower doses of budesonide in inhalation while achieving the same bioavailability.
- Potentially less overall steroid exposure
|
| |
Development Status |
| |
- We are developing three formulations: an inhalation solution for asthma; a nasal spray for nasal allergies; and an ophthalmic solution for allergic conjunctivitis
- AstraZeneca completed Phase 2 trials for inhalation
- We completed Phase 2 trial of nasal spray
|
| Updated: May 29, 2008 | |
